Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema

Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema

Background: Diabetic macular edema (DME) is a leading cause of vision impairment globally among working population, with anti-vascular endothelial growth factor (anti-VEGF) therapies being the standard treatment. The high cost of anti-VEGF drive use of biosimilars like Razumab®. This study provides...

Full description

Saved in:
Bibliographic Details
Main Authors: Dhandapani A, Ravindran S, Muthusamy K, Muruganandham K, Kaliamurty S
Format: Article
Language:English
Published: KIMS Foundation and Research Center 2025-06-01
Series:Journal of Medical and Scientific Research
Subjects:
diabetes macular edema
vascular endothelial growth factor
biosimilar
central subfoveal thickness
Online Access:https://jmsronline.com/archive-article/Ranibizumab-Razumab-diabetic-macular-edema
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items